Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN
hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement"
hVIVO hails $9.2 billion Cidara takeover after key trial wins
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX
Stock Traders Purchase High Volume of Cidara Therapeutics Call Options (NASDAQ:CDTX)
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)
This Biotech's Stock Price More Than Doubled on Friday. Here's Why.
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
Shareholder Alert: The Ademi Firm investigates whether Cidara Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX
Merck to acquire Cidara Therapeutics for $9.2B
CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders
Merck to Buy Cidara Therapeutics in $9.2 Billion Deal
Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring
Merck to acquire Cidara Therapeutics for $9.2B
Merck nearing deal for Cidara, FT reports
Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Cidara Therapeutics to Participate in November Investor Conferences
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
Cidara Therapeutics: A Potential Blockbuster In Flu Prevention
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025